Company | Name | Exchange | Sector | Industry | Market Cap | P/E Ratio | PEG Ratio | Last Trade Price | Day Change (%) | Fair Value | Fair Value Upside | Fair Value Label | Analyst Price Target | Analyst Target Upside | Overall Health |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Eli Lilly and | Xetra | Healthcare | Pharmaceuticals | €686.32B | 85.6x | 1.26 | €764.20 | 4.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Eli Lilly | Vienna | Healthcare | Pharmaceuticals | €685.56B | 85.6x | 1.26 | €758.90 | 4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Eli Lilly and | Frankfurt | Healthcare | Pharmaceuticals | €661.85B | 83.6x | 1.26 | €761.90 | 4.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
UnitedHealth | Vienna | Healthcare | Healthcare Providers & Services | €442.19B | 32.3x | -1.01 | €470 | -0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
UnitedHealth Group | Frankfurt | Healthcare | Healthcare Providers & Services | €440.80B | 32.1x | -1.01 | €480.25 | 1.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Novo Nordisk A S | Xetra | Healthcare | Pharmaceuticals | €350.05B | 28.1x | 1.31 | €79.90 | -19.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Novo Nordisk AS | Vienna | Healthcare | Pharmaceuticals | €350.05B | 28.1x | 1.31 | €79.20 | -20.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Novo Nordisk A S | Frankfurt | Healthcare | Pharmaceuticals | €350.05B | 28.1x | 1.31 | €82.47 | -18% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Novo Nordisk B | BATS Europe | Healthcare | Pharmaceuticals | €349.82B | 28.1x | 1.26 | €78.82 | -20.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Johnson&Johnson | Xetra | Healthcare | Pharmaceuticals | €335.14B | 23.7x | -0.44 | €138.94 | -0.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Johnson & Johnson | Vienna | Healthcare | Pharmaceuticals | €334.96B | 23.8x | -0.44 | €137.92 | -0.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Johnson Johnson | Frankfurt | Healthcare | Pharmaceuticals | €333.10B | 23.7x | -0.44 | €139.24 | 0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
AbbVie | Frankfurt | Healthcare | Pharmaceuticals | €298.31B | 61.3x | -2.81 | €168.42 | 1.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Abbvie | Vienna | Healthcare | Pharmaceuticals | €297.50B | 61x | -2.81 | €166.16 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Merck | Xetra | Healthcare | Pharmaceuticals | €241.40B | 20.7x | 0.13 | €95 | -0.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Merck & Co | Vienna | Healthcare | Pharmaceuticals | €241.03B | 20.8x | 0.13 | €94.90 | -0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Merck | Milan | Healthcare | Pharmaceuticals | €241.03B | 20.8x | -2.2 | €95.20 | -0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Merck | Frankfurt | Healthcare | Pharmaceuticals | €240.20B | 20.7x | 0.13 | €95.10 | 0.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Roche | BATS Europe | Healthcare | Pharmaceuticals | €223.93B | 19.6x | -5.88 | €281.05 | 0.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Roche | BATS Europe | Healthcare | Pharmaceuticals | €223.93B | 19.6x | -5.89 | €266.20 | 0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Roche Holding DRC | Frankfurt | Healthcare | Pharmaceuticals | €223.48B | 19.6x | -5.89 | €33 | -1.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Thermo Fisher Scientific | Vienna | Healthcare | Healthcare Equipment & Supplies | €192.61B | 32.8x | 7.21 | €496.95 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Astrazeneca PLC | Xetra | Healthcare | Pharmaceuticals | €192.29B | 30.8x | 3.22 | €124.55 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
AstraZeneca DRC | Vienna | Healthcare | Pharmaceuticals | €192.29B | 30.8x | 3.22 | €62 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
AstraZeneca DRC | Frankfurt | Healthcare | Pharmaceuticals | €192.29B | 30.8x | 3.22 | €61 | -1.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
AstraZeneca | Frankfurt | Healthcare | Pharmaceuticals | €192.29B | 30.8x | 3.22 | €122.90 | -1.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
AstraZeneca PLC | BATS Europe | Healthcare | Pharmaceuticals | €192.13B | 30.8x | 3.22 | €127.52 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Astrazeneca | BATS Europe | Healthcare | Pharmaceuticals | €191.67B | 30.8x | 3.22 | €123.41 | 0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Abbott Laboratories | Vienna | Healthcare | Healthcare Equipment & Supplies | €190.73B | 34.8x | 2.84 | €108.16 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Abbott Laboratories | Xetra | Healthcare | Healthcare Equipment & Supplies | €190.30B | 34.5x | 2.84 | €108.84 | 0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ |